Data investigation

The Day the Balloon Comes Out

An intragastric balloon is removed on a scheduled date, which makes it an unusually clean experiment in what happens when a weight intervention ends. One group began regaining. The other kept losing.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

An intragastric balloon is placed in the stomach and removed six months later. Everyone knows the date in advance, which makes it an unusually clean experiment in what happens when a weight intervention ends. In this trial, the group whose treatment stopped began regaining. The group whose semaglutide continued kept losing.[1]

What happened at the removal date

Forty adults with a BMI of at least 27 completed the trial, all with a balloon, half of them also starting semaglutide in the second month and continuing it after the balloon came out. Both groups were measured at three, six and twelve months.

Weight lost from baseline. The balloon was removed at six months.[1]
Balloon + semaglutideBalloon alone
At 6 months29.09 ± 3.45 kg18.35 ± 2.80 kg
Change after removal−3.94 kg (still losing)+2.79 kg (regaining)
At 12 months33.03 ± 3.55 kg15.56 ± 2.50 kg
After the balloon came out at six months, the balloon-alone group regained 2.79 kg while the semaglutide group lost another 3.94 kg.

By twelve months the two groups differed by more than double, and the middle row shows why the gap widened after six months. One intervention ended on schedule and its effect began reversing; the other continued, and so did its effect.

Why this shows the theme so clearly

Every withdrawal trial covered on this register shows that weight returns when treatment stops. What makes them harder to read is that people stop drugs for messy reasons at messy times: side effects, cost, supply, a lost prescription, a change of insurance. Discontinuation is entangled with everything that caused it.

A balloon removal is none of those things. It is a scheduled appointment, unrelated to how anyone is doing. So the regain that follows cannot be explained by differences between the people who stopped and the people who continued, because a protocol decided the stopping six months in advance.

That is a cleaner demonstration than the drug-withdrawal literature can usually manage, and it points the same way: these interventions work while they are happening. The trial evidence on stopping a GLP-1 is in what happens when you stop, and what people did afterward in ordinary care is in what people actually do after stopping.

It also sits alongside the surgical version of the same question. Bariatric surgery does not come out on a date, and weight still returns for many people. Weight regain after bariatric surgery covers the randomized trial that now shows what adding semaglutide does for those it failed.

Forty people

Twenty per group, and a twelve-month loss of 33 kg in the combination arm. That is larger than the average in the pivotal tirzepatide trial, from a drug that is not tirzepatide, in forty people at one center. A number that good should prompt questions about the population and the setting rather than enthusiasm.
  • The paper describes itself as a “prospective, randomized cohort”, which names two different designs in one phrase. The full text describes random allocation by sealed envelope, but results are reported only for the forty who completed the study.
  • Baseline weights are not given in the abstract, so 33 kg cannot be converted into a percentage, the measure every other trial reports.
  • Twelve months, with no follow-up after the semaglutide would eventually stop too.
  • Intragastric balloons are a niche intervention, and this says nothing about how the combination would behave outside that setting.

The finding worth keeping is not the size of the numbers. It is their shape: two curves that moved the same way while both treatments were active and turned in opposite directions the moment one of them ended.

Frequently Asked Questions

In this trial, the group with the balloon alone began regaining weight after removal (2.79 kg), while the group also taking semaglutide continued to lose (3.94 kg).
At six months, 29.09 kg lost against 18.35 kg. By twelve months, after the balloon came out, 33.03 kg against 15.56 kg. That is more than double. The groups already differed at six months, and the gap widened because one intervention had ended and the other had not.
Because the stopping was scheduled. People stop drugs for reasons entangled with how they are doing, such as side effects, cost or supply. A balloon removal is a calendar appointment decided six months in advance, so the regain cannot be explained by who chose to stop.
Cautiously. Forty people, twenty per group, at one center, with a twelve-month loss larger than the average in the pivotal tirzepatide trial. The shape of the result is more informative than its size.
This trial does not follow anyone that far. Everything else known about stopping these drugs suggests it would.

References

  1. 1.Barakat KE, Abuhasan DK, Asal MF, et al. Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study Obesity Surgery. 2025. PMID: 41212463.

When Is It Safe to Have the Skin Removed?

Large weight loss leaves skin that does not retract. A review of 12 studies puts the weight plateau at 53 weeks, and the more consequential finding is about what happens if you stop the drug afterward.

6 min read

The Weight Comparison Used 257 People

A 30,458-patient study reported surgery producing 28.3% weight loss against 10.3% on GLP-1s, at lower two-year cost. The cost half uses the whole cohort. The weight half uses 1.6% of one arm.

7 min read

Fat-to-Muscle Ratio: Surgery Versus Drugs

The lean-to-fat ratio improved in both groups at 6, 12 and 24 months. Everyone loses lean tissue when losing weight. The question is the mix, and both interventions improved it.

5 min read

The Line Is Drawn by Surgery

A meta-regression found study arms with greater average weight loss had higher rates of fatty liver disease resolving. The authors say plainly it cannot establish cause, and a handful of surgical arms are pulling the line.

6 min read

The Group That Lost Least Did Best

A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.

6 min read

Surgery Versus GLP-1 Drugs: Reading an Indirect Comparison

A network meta-analysis of 30 trials put surgery about 10 points ahead on total weight loss. Nobody was randomized to surgery versus a drug, and against tirzepatide alone the difference vanished.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.4

Wellorithm

Compounded semaglutide at a flat $247 every 28 days, any dose

8.5

Gala

Moving between compounded and brand without changing seller

7.9

Luvo Health

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →